Das LKH-Universitätsklinikum Graz oder Landeskrankenhaus-Universitätsklinikum Graz ist ein Klinikum der Maximalversorgung in Graz, Österreich, und Teil der Steiermärkischen Krankenanstaltengesellschaft m.b.H.

During the past decade, LKH-Univ. Klinikum Graz conducted 97 clinical trials. In the 10-year time frame, 97 clinical trials started and 51 clinical trials were completed, i.e. on average, 52.6% percent of trials that started reached the finish line to date. In the past 5 years, 51 clinical trials started and 39 clinical trials were completed. i.e. 76.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "LKH-Univ. Klinikum Graz" #1 sponsor was "Eli Lilly and Company" with 16 trials, followed by "Boehringer Ingelheim" with 11 trials sponsored, "Shire" with 6 trials sponsored, "C. R. Bard" with 5 trials sponsored and "Hoffmann-La Roche" with 5 trials sponsored. Other sponsors include 92 different institutions and companies that sponsored additional 67 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "LKH-Univ. Klinikum Graz" #1 collaborator was "Incyte Corporation" with 4 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "ICON plc" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "ARMO BioSciences" with 1 trials as a collaborator. Other collaborators include 51 different institutions and companies that were collaborators in the rest 61 trials.

According to Clinical.Site data, the most researched conditions in "LKH-Univ. Klinikum Graz" are "Crohn's Disease" (6 trials), "Atopic Dermatitis" (5 trials), "Peripheral Arterial Disease" (5 trials), "Ulcerative Colitis" (4 trials) and "Acute Myocardial Infarction" (3 trials). Many other conditions were trialed in "LKH-Univ. Klinikum Graz" in a lesser frequency.

Most popular intervention types in "LKH-Univ. Klinikum Graz" are "Drug" (91 trials), "Device" (33 trials), "Other" (12 trials), "Biological" (9 trials) and "Procedure" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (32 trials), "Baricitinib" (5 trials), "Ontamalimab" (4 trials), "placebo" (4 trials) and "Abemaciclib" (3 trials). Other intervention names were less common.

The vast majority of trials in "LKH-Univ. Klinikum Graz" are 132 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "LKH-Univ. Klinikum Graz". undefined are not yet recruiting, 29 are recruiting, 16 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 70 completed trials in LKH-Univ. Klinikum Graz, 1 suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in LKH-Univ. Klinikum Graz, 4 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 9 trials, and there were also 19 trials that are defined as “Not Applicable".

LKH-Univ. Klinikum Graz has several departments that took part in Clinical trials: "Universitätsklinik für Innere Medizin" - 19 trials, "Medizinische Universität Graz; Universitätsklinik für Neurologie" - 10 trials, "LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie" - 9 trials, "Universitätsklinik für Dermatologie und Venerologie" - 5 trials, "Universitätsklinik für Kinder- und Jugendheilkunde, Klin. Abt. f. Hämato-Onkologie" - 4 trials, "Medizinische Universität Graz, Klinische Abteilung für Rheumatologie und Immunologie" - 3 trials, "Lkh-Univ. Klinikum Graz; Klin. Abt. Für Hämatologie" - 2 trials, "LKH Univ.-Klinikum Graz, Ambulanz für Angiologie" - 2 trials